Corvus Pharmaceuticals, Inc. (CRVS)

Corvus Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-56.83	-27.03	-41.31	-43.24	-6	-46.67
Depreciation & Amortization	0.09	0.15	0.37	0.46	0.63	0.74
Loss (Gain) From Sale of Assets	-	-	-0.02	-	-37.46	-
Loss (Gain) From Sale of Investments	-1.03	-0.89	-0.17	0.24	0.15	-0.64
Loss (Gain) on Equity Investments	2.43	5.28	10.01	4.83	0.23	-
Stock-Based Compensation	2.76	2.15	2.69	4.23	5.75	7.35
Other Operating Activities	31.03	-	-	-	-	-
Change in Accounts Receivable	-0.06	0.56	-0.08	-0.51	-	-
Change in Accounts Payable	0.47	-0.45	0.41	-1.9	1.02	0.45
Change in Other Net Operating Assets	-0.99	-3.71	1.08	-0.83	0.89	1.45
Operating Cash Flow	-22.13	-23.94	-27.02	-36.72	-34.78	-37.32
Capital Expenditures	-	-0.03	-0.27	-0.01	-0.08	-0.03
Sale of Property, Plant & Equipment	-	-	0.02	-	-	-
Investment in Securities	-23.72	15.58	-23.03	21.57	44.85	3.28
Investing Cash Flow	-23.72	15.54	-23.28	21.56	44.77	3.26
Issuance of Common Stock	16.46	7.86	-	62.16	1.31	0.02
Other Financing Activities	13.97	-	-	-	-	-
Financing Cash Flow	30.42	7.86	-	62.16	1.31	0.02
Net Cash Flow	-15.43	-0.54	-50.3	47	11.3	-34.04
Free Cash Flow	-22.13	-23.97	-27.29	-36.72	-34.85	-37.35
Free Cash Flow Per Share	-0.39	-0.50	-0.59	-0.88	-1.18	-1.27
Levered Free Cash Flow	26.32	-15.79	-15.82	-22.52	-19.04	-20.52
Unlevered Free Cash Flow	26.32	-15.79	-15.82	-22.52	-19.04	-20.52
Change in Net Working Capital	-39.75	3.48	-1.38	3.21	-2.01	-1.95

Source: S&P Capital IQ. Standard template. Financial Sources.